Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype
Open Access
- 1 December 2002
- journal article
- other
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 61 (12) , 1090-1094
- https://doi.org/10.1136/ard.61.12.1090
Abstract
Objective: To determine the diagnostic distribution in a consecutive anti-SSA and/or anti-SSB positive population. Methods: A total of 15 937 serum samples from 10 550 consecutive patients were analysed for antinuclear antibodies (ANAs) on HEp-2 cells. Serum samples positive for ANAs were analysed by immunodiffusion and line immunoassay with recombinant SSA-Ro52, natural SSA-Ro60, and recombinant SSB. Results: Among ANA positive patients in whom clinical information was available, 181 consecutive patients with anti-SSA and/or anti-SSB antibodies were identified, Disease associations were systemic lupus erythematosus (SLE) (45.3%), primary Sjögren9s syndrome (pSS) (14.4%), scleroderma (8.8%), RA (7.7%), cutaneous lupus (7.7%), and dermatomyositis (2.2%). The ratio of diagnoses differed according to the anti-SSA/anti-SSB serotype. Scleroderma and dermatomyositis were enriched among mono-Ro52 reactive serum samples (34.2% and 10.5% respectively). Single reactivity towards Ro60 or anti-Ro60 with anti-Ro52 predisposed for SLE (80.0% and 52.2% respectively). Triple reactivity towards Ro52, Ro60, and SSB was primarily linked with SLE (55.8%) followed by pSS (20.9%). Anti-SSA on immunodiffusion increased the chance for SLE (62.8%), whereas isolated anti-SSB reactivity on immunodiffusion was less indicative for SLE (14.3%) and predisposed more for cutaneous lupus (23.8%) and pSS (33.3%). Conclusion: The diagnostic range associated with anti-SSA or anti-SSB reactivity differs significantly according to the detailed serotype defined by line immunoassay and immunodiffusion.Keywords
This publication has 26 references indexed in Scilit:
- Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testingAnnals of the Rheumatic Diseases, 2001
- Autoantibody profiles in the sera of European patients with myositisAnnals of the Rheumatic Diseases, 2001
- The Association of Anti-Ro52 Autoantibodies with Myositis and Scleroderma AutoantibodiesJournal of Autoimmunity, 1999
- Clinical significance of antinuclear antibodies. Comparison of detection with immunofluorescence and enzyme‐linked immunosorbent assaysArthritis & Rheumatism, 1997
- Purification of antigenically intact Ro ribonucleoproteins; biochemical and Immunological evidence that the 52-kD protein is not a Ro proteinClinical and Experimental Immunology, 1995
- Molecular composition of Ro small ribonucleoprotein complexes in human cells. Intracellular localization of the 60- and 52-kD proteins.Journal of Clinical Investigation, 1994
- THE MOLECULAR BASIS OF THE SSA/Ro ANTIGENS AND THE CLINICAL SIGNIFICANCE OF THEIR AUTOANTIBODIESRheumatology, 1993
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982
- Preliminary criteria for the classification of systemic sclerosis (scleroderma)Arthritis & Rheumatism, 1980